PROOF: Pancreatitis-associated Risk Of Organ Failure

Pancreatitis Clinical Trial

— PROOF  

Official title:

PROOF: Pancreatitis-associated Risk Of Organ Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03075605
• Other study ID #: PRO08010374
• Status: Completed
• Start date: May 20, 2008
• Est. completion date: December 31, 2019

Study information

• Verified date: March 2021
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective case control study that compares the initial immune response with severity and outcome in patients with acute pancreatitis.

Description:

This is a prospective case control study that compares the initial immune response with severity and outcome in patients with acute pancreatitis. Therefore, the investigators aim to determine whether etiology of acute pancreatitis, segregates with candidate genetic polymorphisms and their m-RNA expression, as well as whether functional polymorphisms in inflammation regulating genes predict a more severe outcome in acute pancreatits. The investigators anticipate that based on our results that we will provide a more accurate predictor of the clinical course of acute pancreatits and help direct more aggressive or cytokine specific treatment of patients at greater risk of a more severe form of the disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 723
• Est. completion date: December 31, 2019
• Est. primary completion date: July 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• Inclusion criteria for Subjects (all three) Males and females of 16 years of age and older. Body weight at least 40kg Diagnosis of acute pancreatitis by both: Abdominal pain or abdominal localizing signs AND Elevated amylase levels by at-least three times the upper limit of normal and/or elevated lipase levels by at-least three times the upper limit of normal (25, 26). Acute

pancreatitis must be defined by 2 of the 3 following criteria:

• Serum amylase or lipase elevated greater than 3X upper limit of normal
• epigastric acute pancreatitis pain
• abdominal imaging studies demonstrating pancreatic edema, peripancreatic fat stranding or complications or acute pancreatitis Willingness to participate in the study and sign the informed consent. (Children and subjects who are cognitively impaired for temporary reasons as mentioned in the section 4.7 of this protocol will require a representative to sign the informed consent). Inclusion criteria for Controls (all three) Males and females of 18 years of age and older. a. Unrelated family member or a friend of the subject or a patient having blood drawn in general medicine outpatient clinic, without a history of pancreatitis, OR Willingness to participate in the study and sign the informed consent. Additional Inclusion Criteria for subjects with a previous attack of acute pancreatitis: age criteria as defined above.
• Previous severe attack of severe acute pancreatitis requiring a ICU stay of at least 48 hours or evidence of pancreatic necrosis on computerized tomography. Willingness to participate and sign informed consent

Exclusion Criteria:

• Exclusion Criteria for Subjects:

Persons unwilling to sign the informed consent Disorientation secondary to irreversible organic brain damage. Mean corpuscular volume (MCV) of less than 77 in all children of 18 years or younger. Blood transfusion within one week of enrollment Chronic Pancreatitis History of pancreatic cancer History of cancer requiring chemotherapy or radiation within the past 1 year History of organ transplant Subject is a prisoner Pancreatitis due to multiple trauma or surgical complications Exclusion criteria for Controls: Persons unwilling to sign the informed consent

Related Conditions & MeSH terms

• Multiple Organ Failure
• Organ Failure, Multiple
• Pancreatitis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severe Acute Pancreatitis (defined as persistent organ failure)	To compare the initial immune response in patients who developed mild vs. severe disease. To determine whether functional polymorphisms in inflammation regulating genes predicts a more severe outcome in acute pancreatitis.	1 year